Expert Details
BioPharmaceutical Commercialization
ID: 735463
New Jersey, USA
Therapeutic Experience: I-O, Hemophilia, Rheumatology, Endocrinology, Oncology, Immunology, Cardiovascular, Women’s Health, Gastroenterology, CNS, Generics, Oral Health and Biosimilars
Education
| Year | Degree | Subject | Institution |
|---|---|---|---|
| Year: 1995 | Degree: MBA | Subject: International Business | Institution: Lake Forest Graduate School of Management |
| Year: 1990 | Degree: BA | Subject: Accounting / Political Sciences | Institution: Dominican University |
Work History
| Years | Employer | Title | Department |
|---|---|---|---|
| Years: 2011 to Present | Employer: Undisclosed | Title: President | Department: Management Consulting - Biopharmaceuticals |
Responsibilities:Lead management consulting firm, to develop new product commercialization strategies, market valuations, competitive assessments, long-range forecasts, DCFs, etc. Utilize proprietary cross-functional launch road map to identify timing and activity in support of pre-launch / launch preparedness. Provide consulting resources and act as team lead for company licensing and acquisitions from offering, valuation and through to transaction close.• Leadership • New Product Planning • Expert Witness • Portfolio Planning • P & L Responsibility • Marketing • Business Development • Licensing & Acquisitions • Strategy • Tactical Execution • Project Management • Cross Functional Team Lead • Mentoring |
|||
| Years | Employer | Title | Department |
| Years: 2009 to 2011 | Employer: Novo Nordisk | Title: Sr Dr New Product Commercialization | Department: New Product Commercialization |
Responsibilities:Led cross-functional US teams working on pipeline compounds from phase 1 to phase 3 clinical development to ensure optimized speed-to-market and life cycle management in Hemophilia, Diabetes and Rheumatology. Led customer centric engagement strategies. Provided aligned US commercial input into Global Clinical Development and Marketing strategic plans and tactical activities. |
|||
| Years | Employer | Title | Department |
| Years: 2005 to 2007 | Employer: Savient Pharmaceuticals | Title: Sr Dr New Product Planning | Department: New Product Planning |
Responsibilities:Authored corporate investor presentations & product launch plans for pegloticase, a novel orphan biologic, and other compounds/products. Led all commercialization activities and cross-functional pre-launch team, including market analytics, target product profile, input into phase 3 clinical development program, regulatory strategy, publications, market and thought leader engagement, pricing & reimbursement, market research, product positioning, labeling, branding, HEOR, public relations, patient organizations, IP strategy and life cycle management. |
|||
| Years | Employer | Title | Department |
| Years: 2000 to 2005 | Employer: Strategic Partnering International | Title: Co-Founder | Department: Management Consulting |
Responsibilities:Led in- and out-licensing activities for clients including preparation of business development strategy, prospecting, non-confidential and confidential offering memorandums, partner assessment criteria, competitive evaluations, commercial assessments, clinical data presentations, due diligence teams, terms sheets, financial valuations,negotiations, and contract finalization. Worked at all levels of client organizations to establish shared goals and objectives. Collaborated with thought leaders on technology and company positioning. Developed strategic marketing plans and became key resource to client companies. |
|||
| Years | Employer | Title | Department |
| Years: 1995 to 2000 | Employer: Searle Pharmaceuticals | Title: Dr European Business Planning & Development | Department: European Operations |
Responsibilities:Pan-European Business Operations team lead. Member of Celecoxib Commercialization Task Force. Led European market preparation and launch activities for Arthritis Franchise, including COX-2 portfolio.Major Contributions: • Pre-launch and Launch lead for of Celebrex, Bextra, Dynastat, and Arthrotec across Europe • Directed European business development activities including acquisition of cardiovascular product line • in Switzerland, company acquisition in Italy, pain drug in Scandinavia. Worked with general managers to ensure accuracy of NPV’s and presented to senior management for deal closure • Participated in numerous licensing and acquisition transactions, including COX-2 co-promotion with Pfizer and GP2b/3a portfolio. Alliance management team lead in COX-2 collaboration in Europe. Acquisition of Italian pharma company, Swiss cardiovascular product line, Scandinavian pain franchise, French women’s health franchise • Management of European subsidiaries including organizational build, revenue analysis & optimization, and achievement of budget / long-range plan earnings objectives and revenue forecasts • Provided strategic direction and valuation assessments on Portfolio Decision Analysis activities and Pipeline prioritization |
|||
International Experience
| Years | Country / Region | Summary |
|---|---|---|
| Years: 1995 to 2000 | Country / Region: European Union | Summary: Responsible for EU launch of Celebrex, partnership with Pfizer and country operations. |
Career Accomplishments
| Associations / Societies |
|---|
| Healthcare Business Women's Association |
Additional Experience
| Expert Witness Experience |
|---|
| Trade Libel, Incyte v Flexus Biosciences. Product valuations, strategic rationale. Theft of IP, Quinn Emmanuel, Commercial valuation and 10 year look back. |
| Marketing Experience |
|---|
| Launch of Celebrex, Bextra, Dynastat, Arthrotec across Europe. Pre-launch of Novo Thirteen, post-launch marketing NovoSeven. Numerous other drugs. |
| Other Relevant Experience |
|---|
| Therapeutic Experience: I-O, Hemophilia, Rheumatology, Endocrinology, Oncology, Immunology, Cardiovascular, Women’s Health, Gastroenterology, CNS, Generics, Oral Health and Biosimilars High capacity to enter new therapeutic areas to gain in-depth understanding of science and medical and implications for key stakeholders (physicians, payers, patients, etc.) Comprehensive understanding of cross-functional roles and responsibilities to bring compound to market. |